BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Taste the World: Five Food sources That Have Dazzled Worldwide Palates - 2My Enterprising Excursion: Building a Startup
- 3The capacity to understand people on a profound level: Exploring Life's Intricacies
- 4Strengthening through Wellness: Individual Preparation Achievement
- 52026 Golden Globes: How to watch, start time, TV channel, full nominee list and more
- Space Condos to Lift Your Metropolitan Living
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Pick Your Number one sort of blossom
- The Specialty of Compromise: Examples from Reality
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
- Best bar-b-que Style: Which One Is Your Number one?
- The Best Cell phone Brands for Tech Lovers
- Chinese mega embassy could bring security advantages, says No 10
